Laura Prendergast
Stock Analyst at Stifel
(0.72)
# 4,020
Out of 5,042 analysts
12
Total ratings
36.36%
Success rate
-13.89%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Laura Prendergast
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NUVL Nuvalent | Reinstates: Buy | $115 | $93.39 | +23.14% | 1 | Oct 16, 2025 | |
| BDTX Black Diamond Therapeutics | Reinstates: Buy | $8 | $3.93 | +103.56% | 2 | Oct 16, 2025 | |
| RVMD Revolution Medicines | Reinstates: Buy | $85 | $54.48 | +56.02% | 3 | Oct 16, 2025 | |
| ERAS Erasca | Initiates: Buy | $4 | $2.38 | +68.07% | 2 | Oct 16, 2025 | |
| COGT Cogent Biosciences | Initiates: Hold | $16 | $15.13 | +5.75% | 1 | Oct 16, 2025 | |
| MURA Mural Oncology | Initiates: Strong Buy | $18 | $2.09 | +761.24% | 1 | Oct 4, 2024 | |
| NKTX Nkarta | Upgrades: Strong Buy | $16 | $2.41 | +563.90% | 2 | Aug 14, 2024 |
Nuvalent
Oct 16, 2025
Reinstates: Buy
Price Target: $115
Current: $93.39
Upside: +23.14%
Black Diamond Therapeutics
Oct 16, 2025
Reinstates: Buy
Price Target: $8
Current: $3.93
Upside: +103.56%
Revolution Medicines
Oct 16, 2025
Reinstates: Buy
Price Target: $85
Current: $54.48
Upside: +56.02%
Erasca
Oct 16, 2025
Initiates: Buy
Price Target: $4
Current: $2.38
Upside: +68.07%
Cogent Biosciences
Oct 16, 2025
Initiates: Hold
Price Target: $16
Current: $15.13
Upside: +5.75%
Mural Oncology
Oct 4, 2024
Initiates: Strong Buy
Price Target: $18
Current: $2.09
Upside: +761.24%
Nkarta
Aug 14, 2024
Upgrades: Strong Buy
Price Target: $16
Current: $2.41
Upside: +563.90%